Medicine Recommendations

Pain

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Pain: Anti-inflammatory

For the treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment

Prevention and treatment of ischaemia following subarachnoid haemorrhage

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

Chronic Neuropathic Pain

Vitreomacular traction (NICE TA297)

NICE TA297 - Ocriplasmin for treating vitreomacular traction

Bowel obstruction - GI secretions associated with bowel obstruction. 

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment and prophylaxis of schizophrenia

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

COPD

Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

Chronic spontaneous urticaria (NICE TA339)

NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria

Primary and secondary prevention of cardiovascular disease

Bowel obstruction - nausea and vomiting associated with bowel obstruction